Radioimmunodetection of CEA-Producing Tumors Using a Bispecific Antibody Pre-Targeting Method and an In-Labeled Peptide
Colo-rectal cancer has an incidence of 8000 cases per year in The Netherlands. Eventually
50% of them will die as a consequence of this disease.
Treatment consists of resection of the primary tumor, followed by adjuvant chemotherapy in
some patients. The chemotherapeutical agents, however, are only moderately effective with
regard to increase of survival. New treatment modalities are therefore desirable.
Radioimmunotherapy using radioactive labelled antibodies have proven to be effective in
hematologic malignancies. Due to slow absorption in solid tumors however an effective
radiation dose is not yet achieved.
The aim of our study is to bypass this slow tumor uptake by the use of pre-targeting. We
therefore use an unlabeled bispecific antibody infusion. This will be followed several days
later by the infusion of a radiolabeled peptide that binds to the bispecific antibody.
We hypothesise that this small peptide will be readily absorbed by the tumor which is
pre-saturated by the bispecific antibody. As a consequence a higher radiation dose can be
given with a lower toxicity.
Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Diagnostic
Safety evaluation of intravenous injection of In-labeled IMP-205 and hMN-14xm734
Wim Oyen, MD PhD
Radboud University Medical Centre Nijmegen
Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)